ClinicalTrials.gg
RecruitingNCT05338931Updated May 26, 2022

Safety, Tolerability, and Efficacy of AT101 in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

A Phase 1/2 interventional study of AT101(Anti-CD19 Chimeric Antigen Receptor T cell) in B-cell Non Hodgkin Lymphoma, sponsored by AbClon. Recruiting at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2022-05-26.

Sponsored by AbClon · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2022; still recruiting 4 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
82
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 47 studies in Lymphoma, B-Cell with a site in Korea, Republic of — 13 open to participants now, 26 under way, 10 of them phase 3. Lymphoma, B-Cell · Korea, Republic of.

Planned enrollment
31st of 45
82 · median 215
Started
2022
with 4 others
Phase 1/2
12 of 47
6 open now
Primary completion
2030-03
later than 22 of 25 live
Registered
34th of 47
by date

Among the 47 studies in Lymphoma, B-Cell with a site in Korea, Republic of, this one is the 31st largest by planned enrollment of the 45 interventional ones that give a count, is one of 5 that started in 2022, is one of 12 in phase 1/2, reaches primary completion later than 22 of the 25 other live ones, and was the 34th registered.

Lymphoma, B-Cell

885 studies on the registry are indexed under Lymphoma, B-Cell; 286 are open to participants now.

Browse Lymphoma, B-Cell studies →

Open to participants now

13 of the 47 studies in Lymphoma, B-Cell with a site in Korea, Republic of are open now. Recruiting first, the newest first:

7 more — sign in →

All 13 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 209 Lymphoma, B-Cell studies recruiting now, 129 (62%) set no upper age limit and 60 (29%) stop at 75 or younger; 37 take children under 18; 3 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 47 studies in Lymphoma, B-Cell with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Determine MTD based on the safety and tolerability of AT101 and the RP2D for patients with recurrent or non-reactive B-cell NHL.

Read the detailed description

Determine the maximum tolerant dose (MTD) based on the safety and tolerability of AT101 and the recommended dose 2 dose (RP2D) in phase 2 trials for patients with recurrent or non-reactive B cell non-Hodgkin lymphoma (B-cell NHL).

03

Conditions studied

  • B-cell Non Hodgkin Lymphoma

Browse trials for

Keywords

  • Anti-CD19 Chimeric Antigen Receptor T cell
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • B cell non-Hodgkin lymphoma based on WHO classification 2017
  • incompatible with existing standard therapies or have had disease progression, and whose standard therapies do not currently have available standard therapies due to reasons such as intolerance/inadequacies or rejection
  • The (ECOG) performance status (PS) 0 or 1
  • adequate hematological, kidney, liver, lung, heart and bone marrow function without blood transfusion within two weeks prior to screening
  • Those with a minimum of 12 weeks or more
  • In women with childbearing, clinical response tests (serum- or ure-hCG) were negatively identified during this trial
  • Those who have agreed in writing to participate voluntarily in this trial

Exclusion criteria

Exclusion Criteria:

  • Those who have previously had a history of treating homologic autologous hemoblastitis ( HSCT)
  • At101/adcidmilisers, anticancer chemotherapy/adcidms for lymphodeletion or those who are hypersensitive to tocilizumab
  • Those who cannot take autologous blood
  • Those who have received chemotherapy or radiotherapy, excluding lymphodeletion, within two weeks prior to IP administration
  • Persons who have not been recovered ( grade ≤1 or baseline) due to previous treatment
  • Those who have identified a condition that, at the test's discretion, may affect safety and validation during the trial period.
  • Those who have identified the following forces at the time of screening:

    1. Those who have been clinically aware of heart disease within 6 months prior to screening
    2. Those identified as thromboembolic disease, pulmonary embolism or bleeding bleeding diatheses within 6 months prior to screening
    3. Those who have identified a history of malignant tumors other than B-cell non-Hodgkin's lymphoma within five years prior to screening
    4. Those who have undergone major surgery within 4 weeks prior to screening
    5. Those who have undergone non-critical surgery within two weeks prior to screening
  • Childbearing women or men who do not have the will to use effective for a longer period of time, either 12 months after clinical trial period and AT101 administration or when AT101 in the body is not identified
  • Those who have been administered or applied to other IP/ID within 4 weeks of screening
  • Those who are addicted to alcohol and/or medication
  • Those who are unfit or unable to participate in this trial when judged by PI
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
82 participants (estimated)

Study arms

  • Experimental
    AT101(Anti-CD19 Chimeric Antigen Receptor T cell)

    Anti-CD19 Chimeric Antigen Receptor T cell

    Drug: AT101(Anti-CD19 Chimeric Antigen Receptor T cell)

Interventions

  • DrugAT101(Anti-CD19 Chimeric Antigen Receptor T cell)

    Drug pages: Isosorbide · Gossypol-acetic acid

    Anti-CD19 Chimeric Antigen Receptor T cell

    Also known as: AT101

06

What researchers measure

Primary outcomes

  1. Determine the maximum tolerant dose (MTD) and Recommended Phase 2 Dose (RP2D)

    Phase I: Tolerability of AT101 and the recommended dose 2 dose (RP2D) in phase 2 trials

    Time frame: 28 days

  2. Overall response rate (ORR) by Independent assessment

    Phase II: Proportion of subjects whose best overall response in tumor evaluation was evaluated as a complete response or a partial response

    Time frame: 5 years

Secondary outcomes

  1. Overall response rate (ORR) by Investigator assessment

    Proportion of subjects whose best overall response in tumor evaluation

    Time frame: 5 years

  2. Duration of overall response (DOR)

    Time from first response (CR or PR) to the date of initial objectively documented progression

    Time frame: 5 years

  3. Overall survival(OS)

    Time from randomization to death

    Time frame: 5 years

  4. Progression free survival (PFS)

    Time from randomization to disease progression or death

    Time frame: 5 years

  5. Time to response (TTR)

    Time from randomization to CR or PR

    Time frame: 5 years

  6. Event free survival (EFS)

    Time from randomization to progression, subsequent chemotherapy or death

    Time frame: 5 years

  7. Incidence of adverse Event

    Time frame: 5 years

  8. Peak concentration (Cmax) of AT101

    Time frame: 5 years

  9. Area under the concentration versus time curve (AUC) of AT101

    Time frame: 5 years

  10. AT101 transgene expression

    Time frame: 5 years

  11. Replication-competent lentivirus (RCL) as Assessed by quantitative polymerase

    Time frame: 5 years

Other outcomes

  1. Concentration of cytokines

    Time frame: 5 years

  2. CD19 expression

    Time frame: 5 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2022 (actual). Primary completion is estimated for Mar 2030, 96 months after the start.

Of 94 phase 1/2 interventional studies under Lymphoma, B-Cell, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 55 and three quarters within 96. This study's planned 96 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 1, 2022
First posted
Apr 21, 2022
StartActual
Mar 15, 2022
Primary completionEst.
Mar 15, 2030
CompletionEst.
Sep 15, 2030
Last update
May 26, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 26, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05338931
Lead sponsor
AbClon
Responsible party
Sponsor
First posted
Apr 21, 2022
Start date
Mar 15, 2022
Primary completion
Mar 15, 2030 (estimated)
Completion
Sep 15, 2030 (estimated)
Last update
May 26, 2022

Study contacts

Young ha Lee
Contact
yhlee@abclon.com
82-2-2109-1283
Deok-hyun Yoon
principal investigator · Asan Medical Center, 88, Olympic-ro 43-gil, Songpa-gu, Seoul, South Korea

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Isosorbide · Gossypol-acetic acid

Start the discussion